Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 2/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28119075 | 0.82 | PTGS2 (0.44) | PTGS2ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL9911751 | 0.81 | BCAT2 (0.39) | BCAT2PTGS2PDPK1CYP2A6CYP2B6 | |
| SCHEMBL28119077 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AADORA1HSD17B10 | |
| SCHEMBL9631570 | 0.79 | BCAT2 (0.43) | BCAT2PTGS2PDPK1CYP2A6CYP2B6 | |
| Water SCHEMBL11757973 | 0.75 | BCAT2 (0.41) | BCAT2PTGS2FABP4FABP5RXFP1 | |
| SCHEMBL14883258 | 0.72 | BRD4 (0.32) | PDPK1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL11387541 | 0.72 | BCAT2 (0.41) | BCAT2PTGS2PDPK1FABP4FABP5 | |
| SCHEMBL1825367 | 0.71 | BCAT2 (0.47) | BCAT2PTGS2PDPK1CYP2A6CYP2B6 | |
| SCHEMBL3358969 | 0.69 | BCAT2 (0.48) | BCAT2PTGS2PDPK1CYP2A6CYP2B6 | |
| SCHEMBL1681771 | 0.69 | PTGS2 (0.65) | BCAT2PTGS2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839144-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210217973-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | UNIV ARIZONA STATE (US) | 2021-07-15 | — | — | US | disclosed |
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180226593-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-08-09 | — | — | US | disclosed |
| US-9941479-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9365614-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-06-14 | — | — | US | disclosed |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | PHARMASCIENCE INC. (CA) | 2014-11-13 | — | — | US | disclosed |
| US-8765681-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2014-07-01 | — | — | US | disclosed |
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-20130071411-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-7547724-B2 | IAP BIR domain binding compounds | AEGERA THERPEUTICS, INC. | 2009-06-16 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| US-20080014207-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180226593-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | DPYD, DCTD, TYMP | BCAT2 1916/4885PTGS2 3525/4885PDPK1 2084/4885 |
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | DPYD, DCTD, TYMP | BCAT2 1916/4885PTGS2 3525/4885PDPK1 2084/4885 |
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | BCAT2 2156/4885PTGS2 3826/4885PDPK1 2802/4885 |
| US-20080014207-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | BCAT2 2156/4885PTGS2 3826/4885PDPK1 2802/4885 |
| US-20210217973-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | DPYD, DCTD, TYMP | BCAT2 1916/4885PTGS2 3525/4885PDPK1 2084/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | BCAT2 1831/4885PTGS2 3438/4885PDPK1 1683/4885 |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | BIRC2, BIRC7, BIRC5 | BCAT2 2272/4885PTGS2 3762/4885PDPK1 2590/4885 |
| US-20070219140-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC8 | BCAT2 1806/4885PTGS2 3813/4885PDPK1 2951/4885 |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | BCAT2 1236/4885PTGS2 3176/4885PDPK1 2407/4885 |
| US-20130071411-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | BCAT2 1889/4885PTGS2 3993/4885PDPK1 2756/4885 |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | BCAT2 2636/4885PTGS2 4275/4885PDPK1 3386/4885 |
| US-11839144-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | DPYD, DCTD, TYMP | BCAT2 1916/4885PTGS2 3525/4885PDPK1 2084/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | BCAT2 1444/4885PTGS2 3036/4885PDPK1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.